Neighbors once built each other's wealth — then something quietly ended it.

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YO ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

But now, with this new platform, we can create thousands of individually controllable laser beams that can interact with the ...

Debra OConnell will become chairman of Disney Entertainment Television, while Disney's gaming business, led by Sean Shoptaw, will now report to Walden.

For “Titanic the Musical,” Arts Bonita Director Kody C. Jones has assembled a cast of 55 youth and adult actors. This is not ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which regulators could approve within weeks.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Scientists have developed a powerful new computational method that could accelerate the search for next-generation materials capable of turning sunlight into useful chemical energy. The work focuses ...

Structure Therapeutics said on Monday its pill helped patients lose up to 16.3% of their weight, strengthening its bid to challenge Eli Lilly ​and Novo Nordisk in the increasingly competitive race ...

Light-emitting structures that curl off the chip surface could enable advanced displays, high-speed optical communications, ...